Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Consolidated Net Income (2016 - 2025)

Ani Pharmaceuticals' Consolidated Net Income history spans 15 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 367.96% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $78.3 million, up 522.94%, while the annual FY2025 figure was $78.3 million, 522.94% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $27.5 million at Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $27.5 million in Q4 2025 and bottomed at -$24.2 million in Q3 2024.
  • The 5-year median for Consolidated Net Income is -$1.1 million (2021), against an average of -$590050.0.
  • The largest annual shift saw Consolidated Net Income crashed 23365.12% in 2022 before it skyrocketed 1144.71% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$24.1 million in 2021, then surged by 82.53% to -$4.2 million in 2022, then soared by 127.37% to $1.2 million in 2023, then plummeted by 990.12% to -$10.3 million in 2024, then skyrocketed by 367.96% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Consolidated Net Income are $27.5 million (Q4 2025), $26.6 million (Q3 2025), and $8.5 million (Q2 2025).